• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Schrodinger Inc.

    5/20/25 6:44:43 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    8-K
    Schrodinger, Inc. false 0001490978 0001490978 2025-05-16 2025-05-16
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 16, 2025

     

     

    Schrödinger, Inc.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   001-39206   95-4284541
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    1540 Broadway, 24th Floor

    New York, NY

      10036
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s telephone number, including area code: (212) 295-5800

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   SDGR   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Appointment of Chief Financial Officer

    On May 16, 2025 (the “Effective Date”), the Board of Directors (the “Board”) of Schrödinger, Inc. (the “Company”) appointed Richie Jain as Executive Vice President and Chief Financial Officer and Treasurer of the Company, effective immediately. In connection with his appointment as Chief Financial Officer, Mr. Jain will serve as the Company’s principal financial officer.

    Prior to his appointment as Chief Financial Officer of the Company, Mr. Jain, age 41, had served as the Company’s Senior Vice President, Strategic Finance and Head of Corporate and Business Development since February 2024 and was responsible for corporate and business development, venture and equity investments, strategic planning and valuation. Prior to joining the Company, Mr. Jain held positions of increasing responsibility at Morgan Stanley & Co. LLC (“Morgan Stanley”), an investment banking company, from August 2010 until December 2023, where he was most recently a Managing Director in healthcare investment banking and mergers and acquisitions from January 2020 to December 2023. Prior to joining Morgan Stanley, he was an electrical engineer at Boston Scientific Corporation’s cardiac rhythm management business. Mr. Jain received a B.S. in electrical engineering from the University of Michigan and an M.B.A. from the University of Chicago Booth School of Business.

    In connection with his appointment as Chief Financial Officer, Mr. Jain entered into an employment agreement with the Company (the “Employment Agreement”), which became effective as of the Effective Date. Pursuant to the Employment Agreement, Mr. Jain will be paid an annual base salary of $535,000.

    Mr. Jain will be eligible to participate in the Company’s Senior Executive Incentive Compensation Plan (the “Cash Incentive Plan”), which provides for cash incentive payments based upon the attainment of performance targets established by the Compensation Committee of the Board. For 2025 only, subject to and in accordance with the terms of the Cash Incentive Plan, Mr. Jain is eligible for a target bonus of up to 55% of his annualized base salary, prorated for the period beginning on the Effective Date and ending on December 31, 2025. Mr. Jain will also be eligible for a prorated bonus for the period beginning January 1, 2025 and ending on the Effective Date in connection with his prior role at the Company.

    In connection with his appointment as Chief Financial Officer, the Company expects to grant to Mr. Jain a nonstatutory stock option (the “Option”) to purchase up to 18,750 shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”), at an exercise price per share equal to the closing price of the Common Stock on the Nasdaq Global Select Market on the date of grant, which will vest as to 25% of the shares underlying the Option on the first anniversary of the Effective Date and, as to the remaining shares, monthly thereafter until the fourth anniversary of the Effective Date, subject to continued service. The Company also expects to grant to Mr. Jain restricted stock units with respect to 9,375 shares of the Company’s Common Stock, which will vest in equal annual installments over four years beginning at the first anniversary of the vesting commencement date, subject to continued service.

    Mr. Jain will be entitled to participate in the Company’s Amended and Restated Executive Severance and Change in Control Benefits Plan, as amended (the “Executive Severance Plan”). Entitlement to any severance or benefits under the Executive Severance Plan is contingent upon the effectiveness of a release in favor of the Company and compliance with restrictive covenant and other obligations to the Company.

    In addition, Mr. Jain will enter into an indemnification agreement with the Company, the form of which was filed as Exhibit 10.21 to the Company’s Registration Statement on Form S-1 (File No. 333-235890) filed with the Securities and Exchange Commission on January 10, 2020, pursuant to which the Company may be required, among other things, to indemnify Mr. Jain for certain expenses (including attorneys’ fees), judgments, fines and settlement amounts actually and reasonably incurred by him in any action or proceeding arising out of his service as an officer of the Company.


    The foregoing description of the Employment Agreement does not purport to be complete and is qualified in its entirety by the full text of the Employment Agreement, a copy of which is attached as Exhibit 10.1 hereto and incorporated by reference herein.

    Mr. Jain does not have a family relationship with any of the Company’s officers or directors and has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

    Departure of Chief Financial Officer

    On the Effective Date, the Company and Geoffrey Porges, the Company’s Chief Financial Officer, mutually agreed to Dr. Porges’ separation from such role with the Company in order for Dr. Porges to pursue other opportunities. Dr. Porges will remain employed by the Company through June 6, 2025 as an advisor to the senior management team to ensure a smooth transition.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits:

     

    Exhibit

     No. 

      

    Description

    10.1    Employment Agreement, dated May 16, 2025, by and between Schrödinger, Inc. and Richie Jain
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        Schrödinger, Inc.
    Date: May 20, 2025     By:  

    /s/ Yvonne Tran

          Yvonne Tran
          Chief Legal Officer and Corporate Secretary
    Get the next $SDGR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    8/15/2025$20.00Buy → Neutral
    Citigroup
    8/14/2025$25.00Overweight
    Barclays
    7/3/2025$28.00Equal-Weight
    Morgan Stanley
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    12/19/2022$23.00Neutral
    Goldman
    3/1/2022$55.00Buy
    Citigroup
    More analyst ratings

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Schrodinger downgraded by Citigroup with a new price target

    Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00

    8/15/25 8:18:12 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Schrodinger with a new price target

    Barclays initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $25.00

    8/14/25 8:23:26 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Schrodinger with a new price target

    Morgan Stanley resumed coverage of Schrodinger with a rating of Equal-Weight and set a new price target of $28.00

    7/3/25 7:52:31 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chodakewitz Jeffrey was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:37:45 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sender Gary was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:36:31 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lynton Michael was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:35:05 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Schrödinger, Inc. (NASDAQ:SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs ve

    8/15/25 4:30:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Announces Discontinuation of SGR-2921 Program

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, Schrödinger believes the path to development as a combination therapy would be difficult to pursue. The Phase 1 study was supported by preclinical data which had dem

    8/14/25 7:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c

    8/6/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    SEC Filings

    View All

    SEC Form 10-Q filed by Schrodinger Inc.

    10-Q - Schrodinger, Inc. (0001490978) (Filer)

    8/6/25 4:10:02 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    8/6/25 4:07:10 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    6/18/25 4:09:48 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    View All

    Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

    5/29/25 8:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

    3/10/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

    Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

    8/18/22 7:01:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Schrodinger Inc.

    SC 13G - Schrodinger, Inc. (0001490978) (Subject)

    11/13/24 4:30:25 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    2/13/24 5:13:59 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    1/23/24 11:52:31 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Financials

    Live finance-specific insights

    View All

    Schrödinger Reports Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c

    8/6/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

    Schrödinger (NASDAQ:SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, phar

    7/25/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

    SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed across a broad range of B-cell malignancies, including monotherapy responses in patients with CLL and Waldenström macroglobulinemia Management to host a webcast today at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in mul

    6/12/25 7:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care